These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16903995)

  • 1. Indirect costs and cost-effectiveness analysis.
    Ernst R
    Value Health; 2006; 9(4):253-61. PubMed ID: 16903995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Introduction to the theory of pharmaco-economics].
    Kurz X; Dresse A
    Rev Med Liege; 1998 May; 53(5):230-5. PubMed ID: 9689873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany.
    Hamer HM; Spottke A; Aletsee C; Knake S; Reis J; Strzelczyk A; Oertel WH; Rosenow F; Dodel R
    Epilepsia; 2006 Dec; 47(12):2165-72. PubMed ID: 17201718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Costs of schizophrenia - what we know (not)?].
    Salize HJ
    Psychiatr Prax; 2001 Jul; 28 Suppl 1():S21-8. PubMed ID: 11533903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First approaches to the monetary impact of environmental health disturbances in Germany.
    Haucke F; Brückner U
    Health Policy; 2010 Jan; 94(1):34-44. PubMed ID: 19744742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The burden of illness associated with renal cell carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
    Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.
    Michaud K; Messer J; Choi HK; Wolfe F
    Arthritis Rheum; 2003 Oct; 48(10):2750-62. PubMed ID: 14558079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs and quality of life of multiple sclerosis in Austria.
    Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local health care expenditure plans and their opportunity costs.
    Karlsberg Schaffer S; Sussex J; Devlin N; Walker A
    Health Policy; 2015 Sep; 119(9):1237-44. PubMed ID: 26251323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of spillover effects within the family for medical cost-effectiveness analysis.
    Basu A; Meltzer D
    J Health Econ; 2005 Jul; 24(4):751-73. PubMed ID: 15960995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the costs of a limited public sector antiretroviral treatment programme in South Africa.
    Boulle A; Kenyon C; Skordis J; Wood R
    S Afr Med J; 2002 Oct; 92(10):811-7. PubMed ID: 12432807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.
    Lindgren P; Jönsson B; Yusuf S
    J Intern Med; 2004 May; 255(5):562-70. PubMed ID: 15078498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost of lost productivity in pharmacoeconomics analysis. Part II. Survey in the expert group].
    Wrona W; Hermanowski T; Jakubczyk M; Golicki D; Czech M; Niewada M; Kolasa K
    Przegl Epidemiol; 2011; 65(1):153-7. PubMed ID: 21735853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of illness: United States, 1980.
    Parsons PE; Lichtenstein R; Berki SE; Murt HA; Lepkowski JM; Stehouwer SA; Landis JR
    Natl Med Care Util Expend Surv C; 1986 Apr; (3):1-90. PubMed ID: 10313412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of a randomized study comparing radiosurgery with radiosurgery and whole brain radiation therapy in patients with 1 to 3 brain metastases.
    Lal LS; Byfield SD; Chang EL; Franzini L; Miller LA; Arbuckle R; Reasonda L; Feng C; Adamus A; Swint JM
    Am J Clin Oncol; 2012 Feb; 35(1):45-50. PubMed ID: 21293245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis.
    Tran-Duy A; Boonen A; van de Laar MA; Franke AC; Severens JL
    Ann Rheum Dis; 2011 Dec; 70(12):2111-8. PubMed ID: 21857027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A primer on cost-effectiveness analyses for vascular surgeons.
    Barshes NR; Chambers JD; Cantor SB; Cohen J; Belkin M
    J Vasc Surg; 2012 Jun; 55(6):1794-800. PubMed ID: 22608043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.
    Meltzer D
    J Clin Psychiatry; 1999; 60 Suppl 3():32-5; discussion 36-7. PubMed ID: 10073375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.